SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma launches Omeprazole and Sodium Bicarbonate Capsules in US Market

18 Jul 2016 Evaluate

Ajanta Pharma has received the final approval from US Food and Drug Administration (US FDA) and launched Omeprazole and Sodium Bicarbonate Capsules in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc. It is a bioequivalent prescription generic version of Zegerid and the company has launched the product in 2 strengths 20mg/1100mg & 40mg/1100mg capsules.

Omeprazole and Sodium Bicarbonate Capsules is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Application (ANDA) of which it has final approvals for 11 ANDAs; tentative approvals for 1 ANDA; and 14 ANDAs are under review with US FDA. 

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×